Leveraging patented NOL® technology, the PMD-200™, is a monitoring device, that quantifies patients’ physiological response to pain.
By using the PMD-200™ in operating rooms and critical care units, where patients under general anesthesia are unable to communicate their pain, clinicians are able to assess nociception, and titrate analgesic medications – avoiding excessive use or underuse that may result in significant complications.
PMD-200™ is a simple to use, stand alone monitor.
The system consists of a non-invasive finger probe and sensors that acquire multiple physiological signals.
Artificial intelligence algorithms process and analyze dozens of pain-related physiological parameters and derivatives. The information is converted into a real-time index- NOL® (Nociception Level) Index, presented on the PMD-200™ bedside monitor.
NOL® Index varies on a scale where 0 represents no pain response (anti nociception) and 100 represents extreme pain response (nociception). The NOL® index delivers accurate, continuous, and non-invasive nociception monitoring.
* PMD-200™ and its NOL® index are commercially available in Europe, Canada, Australia and Israel. Not commercially available in the U.S.A.
“Nociception Monitoring During General Anesthesia” presented at Medasense’s NOL® Technology Meetup during Euroanaesthesia (ESA) 2017 by Daniel I. Sessler, M.D., Professor and Chair Department of Outcomes Research, Cleveland Clinic, Ohio, USA. A member of Medasense’s advisory board.
"It is clear that current pain assessment approaches in the operating room are limited. The NOL index provides anesthesiologists with a decision support tool to objectively assess and optimize the treatment of a patient’s nociception pain."
Prof. Albert Dahan, MD, Ph.D., Department of Anaesthesiology, Leiden University Medical Center, The Netherlands, Principal Investigator.
"Getting the right dose of anti-nociceptive medications matters. Too little, and patients wake up in pain. Too much, and patients are at risk of drug-related complications."
Prof. Daniel Sessler, Head of Department of Outcomes Research, Cleveland Clinic, Ohio, USA. A member of Medasense’s advisory board.
"I truly believe in the NOL technology. I am convinced it will improve the quality of our anesthesia and impact on patients' recovery."
Prof. Philippe Richebé is Professor and Anesthesiologist at Maisonneuve-Rosemont Hospital, University of Montreal, Quebec, Canada. Principal Investigator, Member of Medasense’s advisory board.
"Our study confirmed that the NOL gives a better assessment of the patient’s nociceptive state than the parameters we currently use in the operating theater."
Dr. Ruth Edry, Head of Acute Pain Service, Anesthesiology, Rambam Medical Center, Haifa, Israel.
Medasense’s nociception monitoring (NOL®) technology can be implemented in standalone devices offered by the company or integrated into third-party medical devices.